Organization | Blood Transfusion Centre of Slovenia

Blood Transfusion Centre of Slovenia Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial

2006

NCT00629018

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Blood Transfusion Centre of Slovenia

Active Ingredients

Drugs in Phase 2 Trials (5)

allogeneic mononuclear cells (1 trial)

autologous cd34+ cells (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

cyclophosphamide (cytoxan) (1 trial)

gemcitabine (gemzar) (1 trial)

Drugs in Phase 1 Trials (1)

allogeneic mesenchymal stem cells (1 trial)

Drugs in Other Trials (1)

umbilical cord mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Cardiomyopathies (Phase 2)

Cardiomyopathy, Dilated (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial APIs: 7